CD19 and neoplasm: These modalities target CD19, which is a surface molecule commonly expressed in several B-cell malignancies, and treatment with CD19-specific CART results in chronic B-cell aplasia in a substantial proportion of patients due to the cytotoxic killing of both tumor cells and B-cell precursors.